Accumulate evidence for IP-10 in diagnosing pulmonary tuberculosis

Area of Science:

• Biomarkers
• Infectious Diseases
• Pulmonary Medicine

Background:

• Pulmonary tuberculosis (PTB) presents a significant global health and economic challenge.
• Accurate detection of PTB is crucial for global TB elimination efforts.
• Interferon gamma-induced protein 10 (IP-10) has emerged as a potential diagnostic marker for PTB since 2007.

Purpose of the Study:

• To assess the diagnostic value of IP-10 for pulmonary tuberculosis (PTB) through a comprehensive meta-analysis.
• To evaluate the sensitivity, specificity, and overall accuracy of IP-10 as a biomarker for PTB detection.

Main Methods:

• A systematic literature search was conducted across major databases (Web of Science, PubMed, Cochrane Library, Embase) up to February 2019.
• Data from 18 studies, including 2836 participants, were analyzed.
• The hierarchical summary receiver operating characteristic (HSROC) model and random effects model were employed to estimate diagnostic performance metrics.

Main Results:

• The pooled sensitivity and specificity of IP-10 for PTB detection were 86% and 88%, respectively.
• The diagnostic odds ratio (DOR) was 43.01, indicating strong discriminatory ability.
• The area under the curve (AUC) was 0.93, demonstrating good accuracy, with no significant heterogeneity observed across various study parameters.

Conclusions:

• IP-10 demonstrates significant promise as a biomarker for distinguishing pulmonary tuberculosis (PTB) from non-TB conditions.
• The findings support the utility of IP-10 in improving the accuracy of PTB diagnosis.